Larotinib/Larotinib purchase channels

Larotrectinib/Larotrectinib received accelerated approval from the U.S. Food and Drug Administration (FDA) in November 2018 for the treatment of Trk-positive solid tumors. Notably, it is the second tissue-agnostic chemotherapy drug approved by the FDA. The original drug larotrectinib has also been put on the market for sale in China, the European Union, Canada and other regions. Since this drug is a prescription drug, you need to select it through the prescription information issued by a doctor when purchasing it.

Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a neurotrophin-activated receptor tyrosine kinase that is mutated in multiple cancer cell types and plays an important role in tumor cell growth and survival. After administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, thereby inducing apoptosis and inhibiting the growth of Trk-overexpressing tumor cells.

The original drug larotrectinib can currently be sold in relevant hospitals or pharmacies in the regions where it is marketed. Although the original drug larotinib is available for purchase in China, the drug has not yet been included in the medical insurance system. The price varies according to the format: for example, large format capsule preparations are expensive, while small format oral liquids are relatively affordable. For consumers looking for a better price, they can consider purchasing larotrectinib versions in overseas markets, but they need to pay attention to the impact that exchange rate fluctuations may have on the price. Meanwhile, generic drugs are also an affordable option worth considering. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.